STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promoter Methylation
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorDongguan People's Hospital
About this trial
To compare the efficacy and safety of Lenvatinib combined with the standard Stupp regimen versus the standard Stupp regimen alone in the treatment of newly diagnosed glioblastoma with MGMT promoter methylation positive.
Eligibility criteria
Qualifiers
Newly diagnosed GBM confirmed by post-op pathology/biopsy, MGMT promoter methylation positive, no prior RT or chemo.
Surgery/biopsy ≤ 21 days before enrollment.
Age 18-75 years any gender.
KPS ≥ 70.
Disqualifiers
Allergy to Lenvatinib, TMZ, or components.
Other malignancies within 5 years or concurrent, or prior anti-tumor therapy.
Concurrent participation in another clinical trial (except observational).
Grade 4 non-hematological toxicity (except hair loss, nausea, vomiting).
Trial design
Treatments tested in this trial
- Lenvatinib
- TMZ (Temozolomide)
- radiotherapy
Treatment groups
138 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov